Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NBIX | Stock Option | Award | $0 | +120K | $0.00 | 120K | Nov 29, 2021 | Common Stock | 120K | $84.74 | Direct | F1 | |
transaction | NBIX | Restricted Stock Unit | Award | $0 | +17.7K | $0.00 | 17.7K | Nov 29, 2021 | Common Stock | 17.7K | Direct | F2, F3 |
Id | Content |
---|---|
F1 | Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. |
F2 | Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. |
F3 | The Restricted Stock Units will vest annually at 25% of the units vesting on each of November 29, 2022, November 29, 2023, November 29, 2024, and November 29, 2025. |